# Clinical Management of Metabolic Syndrome Among the Population Attending Geriatric Outpatient Clinics in Qatar

**Authors:** Susan Mohieldeen Osman, Brijesh Sathian, Biju Bhaskaran, Marwan Ramadan, Haroon Saleh, Asma Abbas, Hanadi Al Hamad

PMC · DOI: 10.7759/cureus.67826 · 2024-08-26

## TL;DR

This study examines how metabolic syndrome is managed in older patients in Qatar, finding high rates of diabetes and hypertension and suggesting the need for better prevention strategies.

## Contribution

The study provides new insights into the clinical management of metabolic syndrome in older adults in Qatar, highlighting prevalent risk factors and treatment patterns.

## Key findings

- 97% of patients aged ≥60 years had metabolic syndrome.
- High rates of diabetes (97.75%) and hypertension (98.25%) were observed.
- Common treatments included amlodipine, metformin, rosuvastatin, and bisoprolol.

## Abstract

Introduction: Research on the clinical management of metabolic syndrome (MetS) among older individuals in Qatar is limited. This study aimed to determine the clinical management of MetS and associated risk factors.

Methods: A retrospective study was conducted to examine the risk factors for MetS (hypertension, diabetes mellitus, obesity, and hyperlipidemia) among patients aged ≥ 60 years who visited geriatric outpatient clinics in Rumailah Hospital, Doha, Qatar between November 1, 2016, and November 1, 2018.

Results: The mean age of the patients was 70.1 years, and 50% were male. Of the study population, 97% had MetS with a 95% confidence interval (95.3-98.7). In addition, 45.5% of the patients were obese, 97.75% had diabetes mellitus, and 98.25% had hypertension. The most commonly prescribed medications for treatment included amlodipine for hypertension, metformin for diabetes mellitus, rosuvastatin for lipid reduction, and bisoprolol for cardiovascular management.

Conclusion: This study found that MetS is common among the population attending geriatric outpatient clinics in Qatar. The majority of these individuals had high rates of diabetes, hypertension, and dyslipidemia. The early identification of at-risk patients through exercise programs may also delay or reverse the risks associated with MetS. More research, especially prospective and population-based studies, is required to improve preventative efforts and optimize treatment options for metabolic syndrome in older persons in Qatar.

## Linked entities

- **Chemicals:** amlodipine (PubChem CID 2162), metformin (PubChem CID 4091), rosuvastatin (PubChem CID 446157), bisoprolol (PubChem CID 2405)
- **Diseases:** metabolic syndrome (MONDO:0000816), diabetes mellitus (MONDO:0005015), obesity (MONDO:0011122), hyperlipidemia (MONDO:0021187)

## Full-text entities

- **Diseases:** obese (MESH:D009765), MetS (MESH:D024821), hyperlipidemia (MESH:D006949), hypertension (MESH:D006973), dyslipidemia (MESH:D050171), diabetes (MESH:D003920)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11423930